Charles River Laboratories International, Inc. (CRL) Price Prediction 2026–2050

Charles River Laboratories International, Inc. is a healthcare services company that provides drug discovery, non-clinical development, and safety testing services across the United States, Europe, Canada, the Asia Pacific, and internationally. Its work supports researchers and pharmaceutical developers through a range of preclinical offerings and related services.

The company operates through segments including Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers, and also offers services to support the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and insourcing solutions, as well as research animal diagnostic services; it engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies, delivering preclinical drug and therapeutic candidates ready for safety assessment; it provides safety assessment services such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.

The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts, and it maintains strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles, as well as a strategic alliance with Francis Crick Institute for antibody-drug conjugate (ADC) drug discovery and development.

Charles River Laboratories International, Inc. trades at a current price of $225.57 with a market capitalization of $10.87B and is ranked 858 by market position.

The stock has a bullish technical and earnings trajectory implied by its near-term and longer-term forecast structure. The current price is supported by a 30-day technical picture showing a range from $186.64 to $272.61, with near-term momentum reflected in a high RSI and price action around key moving averages. The market’s multi-year forecast points to substantial upside in coming years, with the average forecast price rising from the current level toward much higher targets in 2030 and beyond.

From a forecasting perspective, the average price is projected to rise over time to $553.06 by 2030 and to $3,633.56 by 2050, with corresponding ROIs of 145.2% and 1510.8%, respectively, signaling meaningful upside potential if these trajectories materialize.

The multi-year forecast shows meaningful upside through the 2030s and 2040s, with the average price moving from $553.06 in 2030 to $1,567.59 in 2040 and $3,633.56 in 2050. Corresponding ROIs are projected at 145.2% for 2030, 595% for 2040, and 1510.8% for 2050, with sentiment remaining bullish across these horizons.

In earlier years, the forecast emphasizes a continued upward trajectory, with 2026-2029 showing neutral to bullish sentiment and steadily higher average prices (2031: $612.41; 2032: $706.59; 2033: $786.71; 2034: $801.59; 2035: $924.77). The forecast reflects growing upside potential through 2035 and beyond, culminating in substantial long-run gains by 2050. Risks include the usual uncertainties inherent in long-horizon estimates and external factors that could affect healthcare services demand, regulatory environments, and market volatility.

These figures are estimates and not guarantees.

Drivers of the long-term outlook include expansions in drug discovery and safety testing services, potential increases in demand for preclinical models and associated therapies, and continued strategic collaborations that may bolster development capabilities.